Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Boffito

Showing results (41-50 of 300) with videos related to

Pageof 30
Sort By:
Journal of HIV Therapy|February 26, 2005
Nucleoside/nucleotide reverse transcriptase inhibitor drug interactionsYohan P Samarasinghe, Marta Boffito, Giovanni Di Perri
Sexually Transmitted Infections|October 4, 2007
Simvastatin co-prescribed with protease inhibitors despite dangerous drug interactionsKatherine M Coyne, Marta Boffito, Nick Theobald, et al.
Therapeutic Drug Monitoring|May 29, 2007
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individualsLaura Dickinson, David Back, Anton Pozniak, et al.
The Lancet. HIV|May 18, 2020
COVID-19 in patients with HIVRachael Jones, Mark Nelson, Margherita Bracchi, et al.
Journal of the International AIDS Society|November 14, 2014
Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?Andrew Hill, Saye Khoo, David Back, et al.
Antiviral Therapy|October 7, 2016
An open-label, randomized study of the impact on insulin sensitivity, lipid profile and vascular inflammation by treatment with lopinavir/ritonavir or raltegravir in HIV-negative male volunteersPaul Randell, Akil Jackson, Ana Milinkovic, et al.
AIDS (London, England)|August 11, 2007
Stopping antiretroviral therapyStephen Taylor, Marta Boffito, Saye Khoo, et al.
AIDS (London, England)|October 8, 2009
How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trialsAndrew Hill, Jasper van der Lugt, Will Sawyer, et al.
Trials|July 28, 2024
Commentary: The North West London Clinical Trials Alliance: efficiency and innovation in clinical trial deliveryPatrick Kierkegaard, Bowen Su, Richard Wong, et al.
British Journal of Clinical Pharmacology|April 10, 2024
A case report highlighting drug-drug interactions between 3 life-saving treatments: Feminizing hormones, antiretrovirals and antituberculosis drugsTara Suchak, Margherita Bracchi, Maria Mercer, et al.
Pageof 30

Showing results (41-50 of 300) with videos related to

Sort By:
Pageof 30
Journal of HIV Therapy|February 26, 2005
Nucleoside/nucleotide reverse transcriptase inhibitor drug interactionsYohan P Samarasinghe, Marta Boffito, Giovanni Di Perri
Sexually Transmitted Infections|October 4, 2007
Simvastatin co-prescribed with protease inhibitors despite dangerous drug interactionsKatherine M Coyne, Marta Boffito, Nick Theobald, et al.
Therapeutic Drug Monitoring|May 29, 2007
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individualsLaura Dickinson, David Back, Anton Pozniak, et al.
The Lancet. HIV|May 18, 2020
COVID-19 in patients with HIVRachael Jones, Mark Nelson, Margherita Bracchi, et al.
Journal of the International AIDS Society|November 14, 2014
Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?Andrew Hill, Saye Khoo, David Back, et al.
Antiviral Therapy|October 7, 2016
An open-label, randomized study of the impact on insulin sensitivity, lipid profile and vascular inflammation by treatment with lopinavir/ritonavir or raltegravir in HIV-negative male volunteersPaul Randell, Akil Jackson, Ana Milinkovic, et al.
AIDS (London, England)|August 11, 2007
Stopping antiretroviral therapyStephen Taylor, Marta Boffito, Saye Khoo, et al.
AIDS (London, England)|October 8, 2009
How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trialsAndrew Hill, Jasper van der Lugt, Will Sawyer, et al.
Trials|July 28, 2024
Commentary: The North West London Clinical Trials Alliance: efficiency and innovation in clinical trial deliveryPatrick Kierkegaard, Bowen Su, Richard Wong, et al.
British Journal of Clinical Pharmacology|April 10, 2024
A case report highlighting drug-drug interactions between 3 life-saving treatments: Feminizing hormones, antiretrovirals and antituberculosis drugsTara Suchak, Margherita Bracchi, Maria Mercer, et al.
Pageof 30